Lixisenatide
Lixisenatide (Adlyxin)
Lixisenatide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist derived from exendin-4, a peptide found in Gila monster venom, approved for the treatment of type 2 diabetes mellitus. It is marketed as Adlyxin and is used to improve glycemic control in adults with type 2 diabetes, particularly targeting postprandial glucose excursions. Lixisenatide is notable for its short duration of action, making it well-suited for once-daily dosing before the main meal.
Mechanism of Action
Lixisenatide binds to and activates the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion and suppressing glucagon release from alpha cells, thereby lowering both fasting and postprandial blood glucose. It also slows gastric emptying significantly, which blunts the rate of glucose absorption after meals and contributes to its pronounced postprandial glucose-lowering effect. Additionally, it acts on the central nervous system to reduce appetite and caloric intake, which can facilitate modest weight loss.
Evidence by Health Goal(16 goals)
Dosing Protocols
Within 60 minutes before the main meal of the day, preferably at the same meal each day
Initiate at 10 mcg once daily for 14 days to improve gastrointestinal tolerability, then increase to 20 mcg maintenance dose. Administered subcutaneously in the abdomen, thigh, or upper arm. Do not inject intravenously or intramuscularly.
Safety & Side Effects
Lixisenatide has an acceptable safety profile for its approved indication but is a prescription-only medication in all jurisdictions and should only be used under physician supervision. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in patients with renal impairment or a history of pancreatitis.
Possible Side Effects
- !Nausea (most common, particularly during initiation and dose escalation)
- !Vomiting, often associated with dose increases or eating too quickly
- !Diarrhea or constipation due to altered gastrointestinal motility
- !Headache, reported frequently in clinical trials
- !Hypoglycemia, especially when combined with sulfonylureas or insulin
- !Injection site reactions including bruising, erythema, or nodule formation
- !Dizziness and fatigue, particularly early in treatment
- !Rare risk of acute pancreatitis requiring immediate discontinuation
Interactions
- -Significantly delays oral drug absorption due to slowed gastric emptying - administer time-sensitive oral medications such as antibiotics or oral contraceptives at least 1 hour before lixisenatide injection
- -Increases hypoglycemia risk when combined with sulfonylureas (e.g., glipizide, glyburide) - dose reduction of sulfonylurea may be required
- -Increases hypoglycemia risk when combined with basal or bolus insulin - careful glucose monitoring and insulin dose adjustment required
- -May reduce the rate and extent of absorption of acetaminophen and warfarin - monitor INR more closely in anticoagulated patients
- -Concurrent use with other GLP-1 receptor agonists (e.g., semaglutide, exenatide) is contraindicated due to additive gastrointestinal toxicity and overlapping mechanisms
Cost & Where to Buy
Lixisenatide is a prescription-only branded pharmaceutical (Adlyxin); no generic is currently available in the US. Cost varies significantly based on insurance coverage, manufacturer savings programs, and pharmacy. Manufacturer copay cards may reduce out-of-pocket costs substantially for eligible patients.
Search on Amazon